Pharmaceutical Manufacturing Market (By Drug Development Type: Outsource, In-house; By Formulation: Tablets, Capsules, Injectable, Sprays, Suspensions, Powders, Other Formulations; By Route of Administration: Oral, Topical, Parenteral, Inhalations, Other Routes of Administration; By Therapy Area: Cardiovascular Diseases, Pain, Diabetes; By Prescription: Prescription Medicines, Over-the-counter (OTC) Medicines; By Age Group: Children & Adolescents, Adults, Geriatric; By Distribution Channel: Retail, Non-retail) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Pharmaceutical Manufacturing Market, By Drug Development Type

7.1.  Pharmaceutical Manufacturing Market, by Drug Development Type, 2020-2030

7.1.1.    Outsource

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    In-house

7.1.2.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Pharmaceutical Manufacturing Market, By Formulation

8.1.  Pharmaceutical Manufacturing Market, by Formulation, 2020-2030

8.1.1.    Tablets

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Capsules

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Injectable

8.1.3.1.        Market Revenue and Forecast (2016-2030)

8.1.4.    Sprays

8.1.4.1.        Market Revenue and Forecast (2016-2030)

8.1.5.    Suspensions

8.1.5.1.        Market Revenue and Forecast (2016-2030)

8.1.6.    Powders

8.1.6.1.        Market Revenue and Forecast (2016-2030)

8.1.7.    Other Formulations

8.1.7.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Pharmaceutical Manufacturing Market, By Route of Administration

9.1.  Pharmaceutical Manufacturing Market, by Route of Administration, 2020-2030

9.1.1.    Oral

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Topical

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    Parenteral

9.1.3.1.        Market Revenue and Forecast (2016-2030)

9.1.4.    Inhalations

9.1.4.1.        Market Revenue and Forecast (2016-2030)

9.1.5.    Other Routes of Administration

9.1.5.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Pharmaceutical Manufacturing Market, By Therapy Area

10.1.        Pharmaceutical Manufacturing Market, by Therapy Area, 2020-2030

10.1.1.  Cardiovascular Diseases

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Pain

10.1.2.1.      Market Revenue and Forecast (2016-2030)

10.1.3.  Diabetes

10.1.3.1.      Market Revenue and Forecast (2016-2030)

10.1.4.  Cancer

10.1.4.1.      Market Revenue and Forecast (2016-2030)

10.1.5.  Respiratory Diseases

10.1.5.1.      Market Revenue and Forecast (2016-2030)

10.1.6.  Other Diseases

10.1.6.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Pharmaceutical Manufacturing Market, By Prescription

11.1.        Pharmaceutical Manufacturing Market, by Prescription, 2020-2030

11.1.1.  Prescription Medicines

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  Over-the-counter (OTC) Medicines

11.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Pharmaceutical Manufacturing Market, By Age Group

12.1.        Pharmaceutical Manufacturing Market, by Age Group, 2020-2030

12.1.1.  Children & Adolescents

12.1.1.1.      Market Revenue and Forecast (2016-2030)

12.1.2.  Adults

12.1.2.1.      Market Revenue and Forecast (2016-2030)

12.1.3.  Geriatric

12.1.3.1.      Market Revenue and Forecast (2016-2030)

Chapter 13.      Global Pharmaceutical Manufacturing Market, By Distribution Channel

13.1.        Pharmaceutical Manufacturing Market, by Distribution Channel, 2020-2030

13.1.1.  Retail

13.1.1.1.      Market Revenue and Forecast (2016-2030)

13.1.2.  Non-retail

13.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 14.      Global Pharmaceutical Manufacturing  Market, Regional Estimates and Trend Forecast

14.1.        North America

14.1.1.  Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.1.2.  Market Revenue and Forecast, by Formulation (2016-2030)

14.1.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

14.1.4.  Market Revenue and Forecast, by Therapy Area (2016-2030)

14.1.5.  Market Revenue and Forecast, by Prescription (2016-2030)

14.1.6.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.1.7.  Market Revenue and Forecast, by Age Group (2016-2030)

14.1.8.  U.S.

14.1.8.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.1.8.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.1.8.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.1.8.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.1.8.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.1.8.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.1.8.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.1.9.  Rest of North America

14.1.9.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.1.9.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.1.9.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.1.9.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.1.9.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.1.9.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.1.9.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.2.        Europe

14.2.1.  Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.2.2.  Market Revenue and Forecast, by Formulation (2016-2030)

14.2.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

14.2.4.  Market Revenue and Forecast, by Therapy Area (2016-2030)

14.2.5.  Market Revenue and Forecast, by Prescription (2016-2030)

14.2.6.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.2.7.  Market Revenue and Forecast, by Age Group (2016-2030)

14.2.8.  UK

14.2.8.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.2.8.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.2.8.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.2.8.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.2.8.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.2.8.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.2.8.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.2.9.  Germany

14.2.9.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.2.9.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.2.9.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.2.9.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.2.9.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.2.9.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.2.9.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.2.10.               France

14.2.10.1.   Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.2.10.2.   Market Revenue and Forecast, by Formulation (2016-2030)

14.2.10.3.   Market Revenue and Forecast, by Route of Administration (2016-2030)

14.2.10.4.   Market Revenue and Forecast, by Therapy Area (2016-2030)

14.2.10.5.   Market Revenue and Forecast, by Prescription (2016-2030)

14.2.10.6.   Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.2.10.7.   Market Revenue and Forecast, by Age Group (2016-2030)

14.2.11.               Rest of Europe

14.2.11.1.   Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.2.11.2.   Market Revenue and Forecast, by Formulation (2016-2030)

14.2.11.3.   Market Revenue and Forecast, by Route of Administration (2016-2030)

14.2.11.4.   Market Revenue and Forecast, by Therapy Area (2016-2030)

14.2.11.5.   Market Revenue and Forecast, by Prescription (2016-2030)

14.2.11.6.   Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.2.11.7.   Market Revenue and Forecast, by Age Group (2016-2030)

14.3.        APAC

14.3.1.  Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.3.2.  Market Revenue and Forecast, by Formulation (2016-2030)

14.3.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

14.3.4.  Market Revenue and Forecast, by Therapy Area (2016-2030)

14.3.5.  Market Revenue and Forecast, by Prescription (2016-2030)

14.3.6.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.3.7.  Market Revenue and Forecast, by Age Group (2016-2030)

14.3.8.  India

14.3.8.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.3.8.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.3.8.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.3.8.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.3.8.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.3.8.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.3.8.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.3.9.  China

14.3.9.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.3.9.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.3.9.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.3.9.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.3.9.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.3.9.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.3.9.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.3.10.               Japan

14.3.10.1.   Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.3.10.2.   Market Revenue and Forecast, by Formulation (2016-2030)

14.3.10.3.   Market Revenue and Forecast, by Route of Administration (2016-2030)

14.3.10.4.   Market Revenue and Forecast, by Therapy Area (2016-2030)

14.3.10.5.   Market Revenue and Forecast, by Prescription (2016-2030)

14.3.10.6.   Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.3.10.7.   Market Revenue and Forecast, by Age Group (2016-2030)

14.3.11.               Rest of APAC

14.3.11.1.   Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.3.11.2.   Market Revenue and Forecast, by Formulation (2016-2030)

14.3.11.3.   Market Revenue and Forecast, by Route of Administration (2016-2030)

14.3.11.4.   Market Revenue and Forecast, by Therapy Area (2016-2030)

14.3.11.5.   Market Revenue and Forecast, by Prescription (2016-2030)

14.3.11.6.   Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.3.11.7.   Market Revenue and Forecast, by Age Group (2016-2030)

14.4.        MEA

14.4.1.  Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.4.2.  Market Revenue and Forecast, by Formulation (2016-2030)

14.4.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

14.4.4.  Market Revenue and Forecast, by Therapy Area (2016-2030)

14.4.5.  Market Revenue and Forecast, by Prescription (2016-2030)

14.4.6.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.4.7.  Market Revenue and Forecast, by Age Group (2016-2030)

14.4.8.  GCC

14.4.8.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.4.8.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.4.8.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.4.8.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.4.8.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.4.8.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.4.8.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.4.9.  North Africa

14.4.9.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.4.9.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.4.9.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.4.9.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.4.9.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.4.9.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.4.9.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.4.10.               South Africa

14.4.10.1.   Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.4.10.2.   Market Revenue and Forecast, by Formulation (2016-2030)

14.4.10.3.   Market Revenue and Forecast, by Route of Administration (2016-2030)

14.4.10.4.   Market Revenue and Forecast, by Therapy Area (2016-2030)

14.4.10.5.   Market Revenue and Forecast, by Prescription (2016-2030)

14.4.10.6.   Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.4.10.7.   Market Revenue and Forecast, by Age Group (2016-2030)

14.4.11.               Rest of MEA

14.4.11.1.   Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.4.11.2.   Market Revenue and Forecast, by Formulation (2016-2030)

14.4.11.3.   Market Revenue and Forecast, by Route of Administration (2016-2030)

14.4.11.4.   Market Revenue and Forecast, by Therapy Area (2016-2030)

14.4.11.5.   Market Revenue and Forecast, by Prescription (2016-2030)

14.4.11.6.   Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.4.11.7.   Market Revenue and Forecast, by Age Group (2016-2030)

14.5.        Latin America

14.5.1.  Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.5.2.  Market Revenue and Forecast, by Formulation (2016-2030)

14.5.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

14.5.4.  Market Revenue and Forecast, by Therapy Area (2016-2030)

14.5.5.  Market Revenue and Forecast, by Prescription (2016-2030)

14.5.6.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.5.7.  Market Revenue and Forecast, by Age Group (2016-2030)

14.5.8.  Brazil

14.5.8.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.5.8.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.5.8.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.5.8.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.5.8.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.5.8.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.5.8.7.      Market Revenue and Forecast, by Age Group (2016-2030)

14.5.9.  Rest of LATAM

14.5.9.1.      Market Revenue and Forecast, by Drug Development Type (2016-2030)

14.5.9.2.      Market Revenue and Forecast, by Formulation (2016-2030)

14.5.9.3.      Market Revenue and Forecast, by Route of Administration (2016-2030)

14.5.9.4.      Market Revenue and Forecast, by Therapy Area (2016-2030)

14.5.9.5.      Market Revenue and Forecast, by Prescription (2016-2030)

14.5.9.6.      Market Revenue and Forecast, by Distribution Channel (2016-2030)

14.5.9.7.      Market Revenue and Forecast, by Age Group (2016-2030)

Chapter 15.  Company Profiles

15.1.              F. Hoffmann-La Roche Ltd

15.1.1.  Company Overview

15.1.2.  Product Offerings

15.1.3.  Financial Performance

15.1.4.  Recent Initiatives

15.2.              Novartis AG

15.2.1.  Company Overview

15.2.2.  Product Offerings

15.2.3.  Financial Performance

15.2.4.  Recent Initiatives

15.3.              GlaxoSmithKline plc

15.3.1.  Company Overview

15.3.2.  Product Offerings

15.3.3.  Financial Performance

15.3.4.  Recent Initiatives

15.4.              Pfizer, Inc.

15.4.1.  Company Overview

15.4.2.  Product Offerings

15.4.3.  Financial Performance

15.4.4.  Recent Initiatives

15.5.              AstraZeneca

15.5.1.  Company Overview

15.5.2.  Product Offerings

15.5.3.  Financial Performance

15.5.4.  Recent Initiatives

15.6.              Merck & Co., Inc.

15.6.1.  Company Overview

15.6.2.  Product Offerings

15.6.3.  Financial Performance

15.6.4.  Recent Initiatives

15.7.              Johnson & Johnson

15.7.1.  Company Overview

15.7.2.  Product Offerings

15.7.3.  Financial Performance

15.7.4.  Recent Initiatives

15.8.              Sanofi SA

15.8.1.  Company Overview

15.8.2.  Product Offerings

15.8.3.  Financial Performance

15.8.4.  Recent Initiatives

15.9.              Eli Lilly and Company

15.9.1.  Company Overview

15.9.2.  Product Offerings

15.9.3.  Financial Performance

15.9.4.  Recent Initiatives

15.10.           Lonza

15.10.1.               Company Overview

15.10.2.               Product Offerings

15.10.3.               Financial Performance

15.10.4.               Recent Initiatives

Chapter 16.  Research Methodology

16.1.              Primary Research

16.2.              Secondary Research

16.3.              Assumptions

Chapter 17.  Appendix

17.1.              About Us

Glossary of Terms